Drug Type Antibody |
Synonyms M 104AI, M104AI |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization MirimGENE Co. Ltd.Startup |
Active Organization MirimGENE Co. Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Bowel Diseases | Preclinical | KR | MirimGENE Co. Ltd.Startup | 25 May 2024 |